Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade B 88.15 -1.65% -1.48
CELG closed down 1.65 percent on Friday, March 22, 2019, on 76 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Flat
See historical CELG trend table...

Date Alert Name Type % Chg
Jan 3 200 DMA Resistance Bearish 9.60%
Jan 3 Gilligan's Island Sell Setup Bearish Swing Setup 9.60%
Jan 3 Crossed Above 20 DMA Bullish 9.60%
Jan 3 Crossed Above 50 DMA Bullish 9.60%
Jan 3 New Uptrend Bullish 9.60%
Jan 3 Expansion Breakout Bullish Swing Setup 9.60%
Jan 3 Pocket Pivot Bullish Swing Setup 9.60%
Jan 3 Volume Surge Other 9.60%
Jan 3 Above Upper BB Strength 9.60%
Jan 3 Gapped Up Strength 9.60%

Older signals for CELG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Medicine Chemistry Cancer Chemotherapy New Jersey Acute Myeloid Leukemia Antineoplastic Drugs Multiple Myeloma Anemia Celgene Immunosuppressants Solid Tumor Therapies For Cancer Metastatic Breast Cancer Summit Aromatic Amines Myelodysplastic Syndromes Myelofibrosis PDA Ace 536 Cutaneous T Cell Lymphoma Immune Inflammatory Related Diseases Lenalidomide Pomalidomide
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 95.3
52 Week Low 58.59
Average Volume 9,605,613
200-Day Moving Average 82.5822
50-Day Moving Average 87.851
20-Day Moving Average 87.353
10-Day Moving Average 87.812
Average True Range 1.7113
ADX 22.07
+DI 21.6031
-DI 16.2219
Chandelier Exit (Long, 3 ATRs ) 86.10609999999999
Chandelier Exit (Short, 3 ATRs ) 87.39390000000001
Upper Bollinger Band 91.4324
Lower Bollinger Band 83.2736
Percent B (%b) 0.6
BandWidth 9.340034
MACD Line 0.4624
MACD Signal Line 0.3116
MACD Histogram 0.1508
Fundamentals Value
Market Cap 68.96 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 27.29
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.46
Resistance 3 (R3) 90.65 90.08 90.08
Resistance 2 (R2) 90.08 89.49 89.98 89.95
Resistance 1 (R1) 89.11 89.12 88.83 88.92 89.82
Pivot Point 88.54 88.54 88.39 88.44 88.54
Support 1 (S1) 87.57 87.95 87.29 87.38 86.48
Support 2 (S2) 87.00 87.58 86.90 86.35
Support 3 (S3) 86.03 87.00 86.23
Support 4 (S4) 85.84